Clinical Trial

Study of CM313 in Subject With IgA Nephropathy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is divided into two parts (Part A and Part B). This study aims to evaluate the safety and efficacy of CM313 in subjects with primary Immunoglobulin A nephropathy(IgAN), while also observing its Pharmacokinetics(PK) characteristics, Pharmacokinetics(PD) effects, and immunogenicity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-11.
Trial Details
NCT Number NCT06830395
Lead Sponsor Keymed Biosciences Co.Ltd
Conditions IgA Nephropathy
Enrollment 106 participants
Start Date 2025-09
Primary Completion 2027-03 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-19